No abstract available.
Peripheral Blood Stem Cell Transplantation*

No abstract available.
Peripheral Blood Stem Cell Transplantation*

Peripheral blood (PB) CD34+ cells enumeration is currently the most reliable method to guide the timing of stem cell harvest. However, its usage is restricted by being technically challenging, costly, and time-consuming. Immature reticulocyte fraction (IRF) determination, which is simpler and cheaper and has a faster turn-around time, has been proposed for a similar purpose. The purpose of this study is to evaluate the value of IRF in guiding stem cell harvest and examine the correlation between IRF and PB CD34+ cells count. Daily pre-harvest tests, i.e. PB CD34+ cells and IRF from 21 patients scheduled for autologous PBSC transplant were assessed. Stem cells harvests were commenced when the PB CD34+ cell count were more than 10 cell/ul. A total of 205 pre-harvest tests were analysed. Following stem cell mobilisations, both the IRF and PB CD 34+ cell counts rose with a variable pattern. In this study, we observed that the IRF peaks preceded the PB CD34+ count by 2 days. On the day of stem cell harvest, all the peak IRF values were >0.3. The PB CD34+ cell counts correlated with the harvested stem cell yield, whereby r2 = 0.77, p < 0.021. In autologous stem cell mobilisation, we believe that IRF is a useful screening tool to predict the rise of the PB CD34+ cell counts as it is a simple, fast and less costly. An IRF of > 0.3 may be used as a cut-off value for the initiation of PB CD34+ quantifi cation prior to stem cell harvest.
Peripheral Blood Stem Cell Transplantation ; Hematopoietic Stem Cells

Neuroblastoma is one of the most common extracranial solid tumor of childhood, and treatment of refractory neuroblastoma remains a significant clinical problem. Iodine-131-metaiodobenzylguanidine ((131)I-MIBG) therapy is an alternative approach to treat stage IV neuroblastoma. We report the palliative effect of (131)I-MIBG in three cases of relapsed neuroblastoma after autologous peripheral blood stem cell transplantation. (131)I-MIBG is an effective and relatively nontoxic palliative therapy resulting in reduction of pain and prolongation of survival.
Neuroblastoma ; Palliative Care ; Peripheral Blood Stem Cell Transplantation

A study on hemocyte in peripheral blood of women ages of 18 and above in some suburb communes in Th¸i B×nh province has shown that level of average Hb is about 120 - 130 g/l, highest level of it is in ages of 18 -30 (141, 44 g/l) and lowest in ages of 70 and above (123,66g/l). The rate of subjects with Hb level less than average normal threshold (120% g/l) is 24,76%. This rate is 20,16% in ages of 41 -50 and highest rate is 48,48% in ages of 70 and above mild anemia (most common); moderate anemia: uncommon; and severe anemia: 0.
Hemocytes ; Hemoglobins ; Anemia Peripheral Blood Stem Cell Transplantation

From 11/1997 to 8/2000, 11 patients with acute myeloid leukemia (AML) were performed autologous peripheral blood stem cell (PBSC) transplantation without cryopreservation. PBSC were mobilized by high-dose cyclophosphamide plus granulocyte colony-stimulating factor.When WBC count reached>5x109/l, leukapheresis was started and continued for 3 consecutive days. As soon as the third collection was finished, mephalan was given as a conditioning regimen. 24-42 hours after giving melphalan, the collected PBSC which were preserved at +40C were reinfused. Granulocyte macrophage colony-stimulating factor was given during the nardir period until the an ANC> 1x 109/l for 3 consecutive days. All the patients were engrafted with the mean no time to recover ANC> 0.5x109/l and platelet count > 20x109/l was 14 days and 33.8 days. Overall survival and disease free survival at 2 years were 77.7% and 76.1% respectively. In conclusion, autologous PBSC transplantation without cryopreservation in AML is simple and economic method which may be applied in developing countries.
Leukemia, Myelocytic, Acute ; Peripheral Blood Stem Cell Transplantation

Determination absolutely numbers of T lymphocyte subgroup of peripheral blood in 224 healthy adults aged 16-60 (117 males and 106 females). The results were as follow: TCD3 = 1806+/-340 TB/mcl, TCD4 = 869+/-281 TB/mcl, TCD8 = 682+/-233 TB/mcl, TCD4/TCD8 = 1.42+/-0.72, TCD4/TCD3 = 0.52+/-0.24, TCD8/TCD3 = 0.40+/-0.08. The mean quantify of subgroups were also determined by gender and age. These results were for establishing the reference table of TCD3, TCD4, and TCD8 constant of Vietnamese, in collaboration with various authors. They were also used for assessment of immune condition in immune deficiency disorders, especially in HIV/AIDS patients
Lymphocytes ; Peripheral Blood Stem Cell Transplantation ; Acquired Immunodeficiency Syndrome

No abstract available.
Bone Marrow* ; Humans ; Leukemia* ; Peripheral Blood Stem Cell Transplantation*

BACKGROUND: Peripheral blood stem cell transplantation (PBSCT) has been widely used as a substi-tute of bone marrow transplantation for the treatment of various solid tumors or hematologic malig-nancies. The success of PBSCT is correlated with peripheral blood CD34+ cell count per kilogram of the recipient body weight. Standardization of flow cytometric CD34+ cell enumeration was improved by the modified International Society of Hematotherapy and Gene Engineering (ISHAGE) protocol. The purpose of this study was to evaluate the peripheral parameters (WBCs, mononuclear cells, the CD 34+ cells) that may predict the total CD34+ cell count in the harvest product, using the Stem-Kit (Beck-man Coulter Inc., Fullerton, CA, USA). METHODS: The study tested 88 PBSC harvests and peripheral blood (PB) on the day before collection from 26 patients. The CD34+ cells were analyzed using the Stem-Kit. The WBC and MNC count were measured by Coulter STKS (Beckman Coulter Inc.). The correlation and regression analysis between peripheral parameters (WBCs, MNCs, CD34+ cells) and the total CD34+ cell count in the harvest product were performed. RESULTS: The CD34+ cell count per weight (kg) of 88 PBSC harvests was 1.59 +/- 2.61 (0.01 -17.35). The mean number of WBC, MNC, and CD34+ cell in PB prior to harvest were 10.57 +/- 8.36 (1.50 - 32.50) X 10(3)/micro L, 1.85 +/- 1.28 (0.39- 7.43) X 10(3)/micro L, and 17.21 +/- 33.19 (0.12-239.19)/micro L, respectively. With the CD34+ cells numbering under 3/micro L in peripheral blood (PB), we could not harvest more than 0.5 X 10(6) /kg PBSC. With the cells numbering 3-6/micro L (59%) and 10- 20/micro L (89%), however, we could harvest more than 0.5 X 10(6) /kg and 1.0 X 10(6) /kg, respectively. More than 2.0 X 10(6)/kg of PBSC was collected with 10-20/micro L (31%). The peripheral blood CD34+ cell count prior to harvest significantly correlated with the total CD34+ cell count in the harvest product (r=0.97, P<0.05). CONCLUSIONS: Peripheral blood CD34+ cell enumeration using the Stem-Kit was an efficient predictor of when to harvest peripheral blood stem cells after mobilization therapy. We could not collected the CD34+ cell in harvest product of more than 0.5 X 10(6)/kg if the peripheral blood CD34+ cell count was less than 3/micro L.
Body Weight ; Bone Marrow Transplantation ; Cell Count* ; Humans ; Peripheral Blood Stem Cell Transplantation ; Stem Cells*

OBJECTIVE: To explore the influencing factors and countermeasures of infection in leukemia patients after allogeneic peripheral blood hematopoietic stem cell transplantation. METHODS: A total of 126 patients with leukemia admitted in our hospital from August 2016 to March 2018 were selected. The number of infected patients after transplantation was recorded, and the causes of infection were analyzed. RESULTS: Among the 126 patients, 43 were positive for infection, and the infection rate was 34.13%. A total of 89 pathogens were detected, of which bacteria accounted for 64.05%; virus accounted for 22.47%, and fungi accounted for 13.48%. The patient's age, donor type, pre-transplant infection, prophylactic use of antibiotics and aGVHD all were factors influencing the patient's infection (P＜0.05). The follow-up results showed that the incidence of infection in the intervention group significantly decreased after intervention with prevention program (P＜0.05). After reasonable nursing intervention, the incidence of infection in the intervention group after follow-up for 12 months was lower than that in the control group (P＜0.05). CONCLUSION Pre-transplant infection and prophylactic use of antibiotics are factors influencing the infection after allogeneic hematopoietic stem cell transplantation. The incidence of infection can be reduced by reasonable infection prevention.
Graft vs Host Disease ; Hematopoietic Stem Cell Transplantation ; Humans ; Infections ; Leukemia ; Peripheral Blood Stem Cell Transplantation